Hepion (HEPA) Exec Chairman Vincent LoPriore Receives Award

What Happened
Vincent S. LoPriore, Executive Chairman and Director of Hepion Pharmaceuticals (HEPA), was granted 1,345,500 derivative securities (reported as acquired at $0) on 2026-08-19. The Form 4 reports an acquisition price of $0 and a reported value of $0 because this was an equity award/derivative grant rather than a cash purchase.

Key Details

• Transaction date: 2026-08-19; Form 4 filed: 2026-08-21 (timely filing).
• Quantity: 1,345,500 derivative shares/options granted; acquisition price reported $0; total reported value $0.
• Vesting (per filing footnote): 336,375 options vest immediately upon grant; the remaining 1,009,125 vest in equal monthly installments over six months (≈168,188 per month).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Transaction type: Award/Grant of derivative securities (not a purchase, sale, or exercise).

Context
This was an equity award reported as a derivative grant (often options or RSUs on Form 4). It is not an open-market purchase or sale and did not involve cash at the time of grant. The immediate partial vesting (336,375) gives the insider some vested holdings right away; the balance vests monthly over the next six months.